Clinical trial NCT06424301: Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
Official title: Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma (A Two-center Prospective Single Arm Trial)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Retinoblastoma
Refractory
Keywords: retinoblastoma
intravitreal Chemotherapy
Lead sponsor: Eye & ENT Hospital of Fudan University
Sponsor class: OTHER
Collaborators: name: The Eye Hospital of Wenzhou Medical University
First posted: 2024-05-22
Enrollment: 20
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Retinoblastoma (RB) is the most common intraocular malignancy in children and accounts for 11% of all cancers in children under the age of 1 year. Although the incidence of RB is low, approximately 1/15,000 \~ 1/20,000, it tends to metastasize to the intracranial area through the optic nerve pathway leading to poor prognosis for patients with RB. Currently, with the emergence of new administration routes, such as intravitreal and intrarterial chemotherapy, the rate of eye preservation has been effectively improved. However, the use of high doses of chemotherapeutic agents may lead to visual impairments due to long-term retinal toxicity and some tumors recur or become resistant to chemotherapeutic agents after treatment. In such cases, ocular resection is the only option to prevent extraocular metastasis and death.

Therefore, studies on retinoblastoma are currently focused on finding new targeted therapies to increase anti-tumor activity and reduce side effects. In this study, a novel targeting NUDT21 siRNA drug will be used to treat patients with refractory retinoblastoma. This drug promotes tumor apoptosis by regulating the 3'UTR plus tail of SMC1A, which makes the proliferative activity of tumor cells weaken and achieves tumor control. At the same time, since the targeted drug only focuses on tumor cells, it has reduced side effects compared with existing local chemotherapy regimens.

Based on the above background, this study will explore the feasibility and effectiveness of intravitreal injection of NUDT21 siRNA in patients with refractory retinoblastoma through a two-center prospective study.


Eligibility criteria: Inclusion Criteria:

* 1. Patients with retinoblastoma with a somatic mutation of the gene RB1 and active tumor in a single eye, or germinal mutation of RB1 with active tumor/s in an eye and the contralateral eye unaffected, enucleated or without tumor activity. In both cases, relapsed or refractory with the use of systemic, intraarterial or intravitreal chemotherapy or radiotherapy, in accordance with the availability at his/her referral site, in whom enucleation is the only recommended treatment under opinion of the medical team treating the case at the originating referral site. But the patient has a strong desire to preserve the eye.

  2. Normal renal function: serum creatinine: \< 45 μmol/L (0-2 years); \< 57 μmol/L (3-6 years); \< 60 μmol/L (7-10 years); \< 80 μmol/L (11-13 years).

  3. Normal Hepatic function: serum ALT: \< 0,52 μkat/L (de 9 months -12 years); serum AST: 61-80 g/L (8 months - 5 years); 63-83 g/L (5-9 years); 63-82 g/L (9-12 years).

  4. Adequate marrow reserve manifested in an absolute neutrophil count \> 1000 / mm3, platelets \> 100,000 / mm3 and hemoglobin\> 8 g / dl, without transfusional or cytokine support at least one month prior to study entry.

  5. Age greater than 6 months at the time of inclusion in the study. 6. Sign the informed consent form and be willing to follow up at the specified time.

Exclusion Criteria:

* 1. Presence of factors that require immediate enucleation of the affected eye such as glaucoma, rubeosis iridis, anterior chamber involvement.

  2. Comorbidities: Uncontrolled epilepsy with anticonvulsant treatment, cardiac disease not compensated by treatment.

  3. Active Infections. 4. Other chronic or active acute diseases that under the criterion of the researcher were an exclusion criterion.

  5. History of having received attenuated or live vaccines in the 30 days prior to inclusion in the study.

  6. Any cause of Immunosuppression. 7. Trilateral Retinoblastoma. 8. Extraocular spread. 9. History of having received treatment for retinoblastoma with chemotherapy or radiation therapy by any means within 30 days prior to inclusion in the study.

  10. Patients who can not complete the study procedures.

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: 49 days
Secondary outcomes:
measure: Tumor response
timeFrame: 28 days
measure: Targeting NUDT21 siRNA drugs
timeFrame: 49 days
measure: Immune response
timeFrame: 49 days
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan Eye & ENT Hospital
Study officials:
affiliation: Fudan Eye & ENT Hospital
name: Chen Zhao, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Fudan Eye & ENT Hospital
name: Kang Xue, MD
role: STUDY_DIRECTOR
affiliation: The Eye Hospital of Wenzhou Medical University
name: Kang Zhang, MD
role: STUDY_DIRECTOR
affiliation: Fudan Eye & ENT Hospital
name: Jiang Qian, MD
role: STUDY_DIRECTOR
References: